The Science
A platform engineered for tumor selectivity
Patented, monoclonal-antibody-derived therapeutic leads — designed to act precisely on cancer cells. All findings below are preclinical and in vitro unless otherwise noted.
The Platform
Multiple modalities, one mission
XFBiologics develops patented, monoclonal-antibody-derived therapeutic leads in partnership with established R&D groups in the US and Canada. The technology platform spans plasmid DNA, fusion proteins, AD5 viral vectors, and stem-cell approaches, generating tumor-selective candidates for cancer and infectious disease.
Mechanism of Action
Bind, sequester, and trigger programmed cell death
An illustrative view of how our fusion-protein candidates are designed to work. Claims are preclinical and mechanistic.
- 1
Selective binding
The fusion-protein candidate selectively binds cancer cells while sparing tested normal-cell controls in preclinical models.
- 2
Lysosomal sequestration
In preclinical models the candidate is sequestered in the lysosome/endosome of the cancer cell.
- 3
Programmed cell death
This is designed to trigger apoptosis and autophagy — dysfunctional cellular components are degraded via the lysosome and recycled.
On autophagy: dysfunctional cellular components are degraded via the lysosome and recycled — a self-degradation process the candidate is designed to engage alongside apoptosis.
Selectivity
A preclinical signal of selectivity
In the company's preclinical lysosomal-entry assays, the candidate showed high entry into TNBC cell lysosomes — versus a reported 3–10% lysosomal entry for the leading standard-of-care drug.
OTM001 (preclinical assay)
High entry
into TNBC cell lysosomes, in preclinical lysosomal-entry assays.
Leading drug, reported
3–10%
reported lysosomal entry. The leading drug is a >$10B/yr franchise — noted to frame the market, not to claim superiority.
We frame this as a preclinical signal of selectivity, not a claim of clinical superiority.
Preclinical evidence
Tested broadly — selectivity is the headline
Across in-vitro, 3D, and in-vivo preclinical models. Normal-cell controls showed no cell death.
Tested across breast, bladder, B-cell leukemia, cervical, head & neck, glioblastoma, liver, lung, melanoma, ovarian, and prostate lines (in vitro). Normal breast and liver control cells showed no cell death — selectivity is the headline.
Relative in-vitro cell death by type (preclinical, illustrative). Normal-cell controls shown in grey.
Delivery
pDNA + lipid nanoparticles
Lipid nanoparticles — the technology behind mRNA COVID-19 vaccines — encapsulate genetic material using cationic lipids, PEGylated lipids, phospholipids, and cholesterol. XFBiologics uses DNA-based LNP delivery for greater stability, lower storage burden, and reduced production cost versus mRNA.
- Cationic lipids — encapsulate the DNA payload
- PEGylated lipids — stability & circulation
- Phospholipids — structural bilayer
- Cholesterol — membrane integrity
Research models
Human-relevant preclinical systems
Organoids
3D stem-cell-derived models that mimic human organs for more accurate preclinical study.
Organs-on-a-chip
Microfluidic devices giving human-organ-specific readouts and reducing reliance on animal testing.
IP & Manufacturing
Protected and production-ready
Intellectual property
Issued 20-year patents (USPTO & EU) plus international PCT coverage.
pDNA manufacturing
Plasmid DNA produced under cGMP.
Fill & finish
Formulation and fill/finish at the company's pilot facility in Singapore.